Facilitate Successful Research Collaborations
Adopting best practices and avoiding common collaboration pitfalls
A value proposition for your research collaborations:
Top notch collaborations generate strong data
Strong data leads to informed decisions
Informed decisions result in proper resource allocation
Proper resource allocation allows for new/expanded drug usage
Wider drug usage results in better served patients
Better served patients contribute to a stronger financial bottom line
Do you want your collaborations with outside researchers to provide maximum value to your organization? Learn how from Stewart Lyman, Ph.D., who headed one of the largest and most productive Extramural Research programs in the industry at Immunex Corporation. His presentation distills the expertise his group developed while handling nearly 900 new and ongoing research collaborations yearly. If you want collaborations working harder to fulfill your business and scientific objectives, why not take advantage of his experience?
Presentation Topics Include:
• Philosophical underpinnings of a successful collaboration program
• Benefits (and downsides) of extramural research
• Questions to ask when setting up a program
• Establishing formal collaboration guidelines
• Scaling up your program as your company grows
• Publication and presentation issues
• Interacting productively with collaborators
• Data storage and distribution options
• Designing a strong Material Transfer Agreement (MTA)
• The concept and best use of data gatekeepers
• Reagent packaging and shipping
• Issues for legal, clinical, and regulatory groups
• How to handle collaborators who misuse your reagents
• Working with university technology transfer groups
Questions Answered Include:
• What is the best method of sharing data with others in the company?
• Are you obligated to fill all reagent requests from academic and industry scientists?
• What is the best way to receive and handle reagent and collaboration requests?
• Should you pay your extramural collaborators?
• Is it a good idea to send out a molecule that is already in the clinic?
• Should you set up overlapping collaborations with different researchers?
• At what stage of a research program is it appropriate to send reagents to outside collaborators?
• How should you deal with negative data?
• Should you send out "surrogate" drugs?
Who should attend:
This presentation teaches best-in-industry practices to senior managers, research staff, and members of your legal, clinical, development, and regulatory groups that interact with your researchers.
me at (206) 931-6403 and arrange a presentation